Insititute for Clinical Pharmacodynamics: Publications

BY AUTHOR

Okusanya OO, Bhavnani SM, Hammel J, Minic P, Dupont LJ, Forrest A, Mulder GJ, Mackinson C, Ambrose PG, Gupta R.
Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother 2009 Sep; 53(9):3847-54.

Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS.
Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 2009 Aug; 22(4):279-85.

Van Wart SA, Andes DR, Ambrose PG, Bhavnani SM.
Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis 2009 Apr; 63(4):409-14.

Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Bhavnani SM, Ellis-Grosse EJ.
Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagn Microbiol Infect Dis 2009 Feb; 63(2):155-9.

Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Rubino CM, Korth-Bradley JM, Babinchak T, Ellis-Grosse EJ.
Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints. Diagn Microbiol Infect Dis 2009 Feb; 63(2):155-9.

Jones RN, Biedenbach DJ, Ambrose PG, Wikler MA.
Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains. Diagn Microbiol Infect Dis 2008 Sep; 62(1):110-2.

Bradley JS, Sauberan JB, Ambrose PG, Bhavnani SM, Rasmussen MR, Capparelli EV.
Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. Pediatr Infect Dis J 2008 Sep; 27(9):794-9.

Bhavnani SM, Forrest A, Hammel JP, Drusano GL, Rubino CM, Ambrose PG.
Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia. Diagn Microbiol Infect Dis 2008 Sep; 62(1):99-101.

Ambrose PG, Anon JB, Bhavnani SM, Okusanya OO, Jones RN, Paglia MR, Kahn J, Drusano GL.
Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis. Diagn Microbiol Infect Dis. 2008 May;61(1):21-2.

Passarell JA, Meagher AK, Liolios K, Cirincione BB, Van Wart SA, Babinchak T, Ellis-Grosse EJ, Ambrose PG.
Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2008 Jan;52(1):204-10.

Bhavnani SM, Ambrose PG.
Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. Diagn Microbiol Infect Dis 2008 Jan; 60(1):59-64.

Ambrose PG, Forrest A, Craig WA, Rubino CM, Bhavnani SM, Drusano GL, Heine HS.
Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. Antimicrob Agents Chemother. 2007 Dec;51(12):4351-5. Epub 2007 Sep 17.

Rubino CM, Ma L, Bhavnani SM, Korth-Bradley J, Speth J, Ellis-Grosse E, Rodvold KR, Ambrose PG, Drusano GL.
Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation. Antimicrob Agents Chemother. 2007 Nov;51(11):4085-9. Epub 2007 Sep 10.

Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A.
Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007 Sep 15;45(6):753-60. Epub 2007 Aug 8.

Rubino CM, Ambrose P, Cirincione B, Arguedas A, Sher L, Lopez E, Sáez-Llorens X, Grasela DM.
Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development. Diagn Microbiol Infect Dis. 2007 Sep;59(1):67-74.

Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, Drusano GL.
Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother. 2007 Jul;51(7):2329-36. Epub 2007 Apr 16.

Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, Ellis-Grosse EJ, Ambrose PG.
Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother. 2007 Jun;51(6):1939-45. Epub 2007 Mar 12.

Owens RC Jr, Ambrose PG.
Antimicrobial stewardship and the role of pharmacokinetics-pharmacodynamics in the modern antibiotic era. Diagn Microbiol Infect Dis. 2007 Mar;57(3 Suppl):77S-83S. Epub 2007 Feb 9.

Sader HS, Bhavnani SM, Ambrose PG, Jones RN, Pfaller MA.
Re-evaluation of the role of broad-spectrum cephalosporins against staphylococci by applying contemporary in vitro results and pharmacokinetic-pharmacodynamic principles. J Chemother. 2007 Feb;19(1):38-43.

Gumbo T, Louie A, Liu W, Ambrose PG, Bhavnani SM, Brown D, Drusano GL
Isoniazid's Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion of Mycobacterium tuberculosis in the Log Phase of Growth. J Infect Dis. 2007 V195:194-201.

Anon JB, Paglia M, Xiang J, Ambrose PG, Jones RN, Kahn JB.
Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis. Diagn Microbiol Infect Dis. 2007 Jan;57(1):105-7.

Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL.
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore. 2007 Jan 1;44(1):79-86.

Smith PF, Tsuji B, Booker BM, Forrest A, Bajic S, Kelchlin P, Bhavnani SM, Jones RN, Ambrose PG.
Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model. Diagn Microbiol Infect Dis. 2006 Dec;56(4):379-86.

Ramphal R, Ambrose PG.
Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis. 2006 Apr 15;42 Suppl 4:S164-72.

Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D.
Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006 Apr;50(4):1570-2.

Bhavnani SM, Passarell JA, Owen JS, Loutit JS, Porter SB, Ambrose PG.
Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006 Mar;50(3):994-1000.

Bhavnani SM, Ambrose PG, Craig WA, Dudley MN, Jones RN.
Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 2006 Mar;54(3):231-6.

Ambrose PG.
Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists. Pharmacotherapy. 2006 Jan;26(1):129-34. Review.

Hammel JP, Bhavnani SM, Jones RN, Forrest A, Ambrose PG.
Comparison of censored regression and standard regression analyses for modeling relationships between antimicrobial susceptibility and patient- and institution-specific variables. Antimicrob Agents Chemother. 2006 Jan;50(1):62-7.

Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG.
Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother. 2005 Sep;49(9):3944-7.

Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ.
The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S333-40.

Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG.
Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother. 2005 Sep;49(9):3944-7.

Jones RN, Craig WA, Ambrose PG, Dudley MN, Pottumarthy S.
Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases. Diagn Microbiol Infect Dis. 2005 Jul;52(3):235-46.

Owens RC Jr, Ambrose PG.
Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S144-57.

Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ.
Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis. 2005 Jul;52(3):165-71.

Booker BM, Smith PF, Forrest A, Bullock J, Kelchlin P, Bhavnani SM, Jones RN, Ambrose PG.
Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. Antimicrob Agents Chemother. 2005 May;49(5):1775-81.

Ambrose PG.
Framing the threat of resistance to quinolones in pharmacologic terms. Manag Care Interface. 2005 Apr;Suppl:4-6.

Fetterly GJ, Ong CM, Bhavnani SM, Loutit JS, Porter SB, Morello LG, Ambrose PG, Nicolau DP.
Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother. 2005 Jan;49(1):148-52.

Fetterly GJ, Ong C, Bhavnani SM, Loutit J, Porter S, Ambrose PG, Nicolau DP.
Characterization of oritavancin (ORI) pharmacokinetics (PK) in plasma and blister fluid in normal healthy volunteers. Antimicrobial Agents and Chemotherapy, 2005; 49: 148-152.

Bhavnani SM, Hammel JP, Jones RN, Ambrose PG.
Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn Microbiol Infect Dis. 2005 Jan;51(1):31-7.

Ambrose PG.
Antimicrobial susceptibility breakpoints: PK-PD and susceptibility breakpoints. Treat Respir Med. 2005;4 Suppl 1:5-11.

Owens RC Jr, Bhavnani SM, Ambrose PG.
Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2005 Jan;51(1):45-9.

Craig WA, Bhavnani SM, Ambrose PG.
The inoculum effect: fact or artifact? Diagn Microbiol Infect Dis. 2004 Dec;50(4):229-30.

Van Wart S, Phillips L, Ludwig EA, Russo R, Gajjar DA, Bello A, Ambrose PG, Costanzo C, Grasela TH, Echols R, Grasela DM.
Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2004;48:4766-77.

Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG.
Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagnostic Microbiology and Infectious Disease Diagn Microbiol Infect Dis. 2004 Oct;50(2):95-102.

Ambrose PG, Anon JB, Owen JS, Van Wart S, McPhee ME, Bhavnani SM, Piedmonte M, Jones RN.
Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. Clin Infect Dis. 2004 Jun 1;38(11):1513-20.

Anon JB, Jacobs MR, Poole MD, Ambrose PG, Benninger MS, Hadley JA, Craig WA.
Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 2004 Jun;130(6):794-6.

Ambrose PG, Bast D, Doern GV, Iannini PB, Jones RN, Klugman KP, and Low DE.
Fluoroquinolone-resistant Streptococcus pneumoniae, an emerging but unrecognized public health concern: is it time to resight the goalposts? Clinical Infectious Diseases 2004;39:1554-1556.

Ambrose PG, Bhavnani SM, Owens RC Jr.
Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am. 2003 Sep;17(3):529-43.

Ambrose PG, Bhavnani SM, Cirincione BB, Piedmonte M, Grasela TH.
Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother. 2003 Sep;52(3):435-40.

Bhavnani SM, Hammel JP, Forrest A, Jones RN, Ambrose PG.
Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of Gram-negative pathogens. Clin Infect Dis. 2003 Aug 1;37(3):344-50.

Ambrose PG, Bhavnani SM, Jones RN.
Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Antimicrob Agents Chemother. 2003 May;47(5):1643-6.

Jones RN, Rubino CM, Bhavnani SM, Ambrose PG.
Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae . Antimicrob Agents Chemother. 2003 Jan;47(1):292-6.

Owens RC Jr, Ambrose PG.
Torsades de pointes associated with fluoroquinolones. Pharmacotherapy. 2002 May;22(5):663-8; discussion 668-72.

Ambrose PG, Owens RC Jr, Garvey MJ, Jones RN.
Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother. 2002 Mar;49(3):445-53.

Bhavnani SM, Ambrose PG, Jones RN.
Pharmacodynamics in the evaluation of drug regimens. Ann Pharmacother. 2002 Mar;36(3):530-2.

Nicolau DP, Ambrose PG.
Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae . Am J Med. 2001 Dec 17;111 Suppl 9A:13S-18S; discussion 36S-38S.

Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF.
Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2001 Oct;45(10):2793-7.

Bui KQ, Ambrose PG, Nicolau DP, Lapin CD, Nightingale CH, Quintiliani R.
Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients. Chemotherapy. 2001 May-Jun;47(3):153-6.

Owens Jr RC, Tessier P, Nightingale CH, Ambrose PG, Quintiliani R, Nicolau DP.
Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens. Int J Antimicrob Agents. 2001 Jun;17(6):483-9.

Grant EM, Ambrose PG, Nicolau DP, Nightingale CH, Quintiliani R.
Clinical efficacy of cefepime in pneumonia caused by Pseudomonas aeruginosa. J Infect Dis Pharmacother 2001; 5:43-55.

Drusano GL, Preston SL, Owens RC Jr, and Ambrose PG.
Fluoroquinolone Pharmacodynamics. Clinical Infectious Diseases 2001;33 (12):2091-6.

Ambrose PG, Owens Jr RC, Grasela D.
Antimicrobial pharmacodynamics. Med Clin North Am. 2000 Nov;84(6):1431-46.

Owens RC Jr, Ambrose PG.
Clinical use of the fluoroquinolones. Med Clin North Am. 2000 Nov;84(6):1447-69. Review.

Ambrose PG, Grasela DM.
The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2000 Nov;38(3):151-7.

Dudley MN, Ambrose PG.
Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Curr Opin Microbiol. 2000 Oct;3(5):515-21.

Ambrose PG, Quintiliani R.
Limitations of single point pharmacodynamic analysis. Pediatr Infect Dis J. 2000 Aug;19(8):769.

Grant EM, Zhong MK, Ambrose PG, Nicolau DP, Nightingale CH, Quintiliani R.
Stability of meropenem in a portable infusion device in a cold pouch. Am J Health Syst Pharm. 2000 May 15;57(10):992-5.

Mason EO Jr, Lamberth LB, Kershaw NL, Prosser BL, Zoe A, Ambrose PG.
Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis. J Antimicrob Chemother. 2000 May;45(5):623-31.

Ambrose PG, Anon J, Benninger MS, Bernstein JM, Besser RE, Craig WC, et al.
Antimicrobial treatment guidelines for Acute bacterial rhinosinusitis. Otolaryngology-Head and Neck Surgery 2000; 123(supple.A):1A-32A.

Ambrose PG, Owens Jr RC.
New antibiotics in pulmonary and critical care medicine: focus on advanced generation quinolones and cephalosporins. Semin Respir Crit Care Med. 2000;21(1):19-32.